D-Wave Quantum Completes Proof-of-Concept Project in Drug Discovery With Japan Tobacco's Drug Unit

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

D-Wave Quantum Completes Proof-of-Concept Project in Drug Discovery With Japan Tobacco's Drug Unit

, MT Newswires - 10:40 AM ET 3/31/2025 default

10:40 AM EDT, 03/31/2025 (MT Newswires) -- D-Wave Quantum ( QBTS ) and the pharmaceutical division of Japan Tobacco said Monday that they completed a joint proof-of-concept project adapting D-Wave's quantum computing technology and artificial intelligence for the drug discovery process.

The companies developed hybrid large language models that generated "more valid" molecules with a higher quantitative estimate of drug-likeness, compared with classical methods alone, they said.

Following the proof-of-concept project, Japan Tobacco's pharmaceutical division now plans to further advance development of quantum AI-driven drug discovery technology for molecular design, the companies said.

Price: 7.59, Change: +0.01, Percent Change: +0.15

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.